Cascade of immunologic adverse events related to pembrolizumab treatment
(2019) BMJ Case Reports — Vol. 12, n° 6, p. e229149 (2019)
Files
e229149.full.pdf
Open Access - Adobe PDF
- 573.54 KB
Details
- Authors
- Abstract
- Immune checkpoint inhibitors, such as pembrolizumab, have significantly improved cancer patient outcome. Toxicities are usually moderate and manageable. However, some adverse events, if not early recognised, could be life-threatening. We report a patient with non-small cell lung cancer who received treatment with pembrolizumab and developed multiple immune-related adverse events both during and after completing treatment, including rash, pericarditis, colitis and myasthenia gravis.
- Affiliations
Hopital de Jolimont, Haine-Saint-Paul, Belgium Department of Medical Oncology Hopital de Jolimont, Haine-Saint-Paul, Belgium Department of Gynecology
Citations
Dhenin, A., Samartzi, V., Lejeune, S., & Seront, E. (2019). Cascade of immunologic adverse events related to pembrolizumab treatment. BMJ Case Reports, 12(6), e229149. https://doi.org/10.1136/bcr-2018-229149 (Original work published 2019)